246 related articles for article (PubMed ID: 23983061)
1. Gain of 1q is associated with inferior event-free and overall survival in patients with favorable histology Wilms tumor: a report from the Children's Oncology Group.
Gratias EJ; Jennings LJ; Anderson JR; Dome JS; Grundy P; Perlman EJ
Cancer; 2013 Nov; 119(21):3887-94. PubMed ID: 23983061
[TBL] [Abstract][Full Text] [Related]
2. Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group.
Gratias EJ; Dome JS; Jennings LJ; Chi YY; Tian J; Anderson J; Grundy P; Mullen EA; Geller JI; Fernandez CV; Perlman EJ
J Clin Oncol; 2016 Sep; 34(26):3189-94. PubMed ID: 27400937
[TBL] [Abstract][Full Text] [Related]
3. Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532.
Fernandez CV; Mullen EA; Chi YY; Ehrlich PF; Perlman EJ; Kalapurakal JA; Khanna G; Paulino AC; Hamilton TE; Gow KW; Tochner Z; Hoffer FA; Withycombe JS; Shamberger RC; Kim Y; Geller JI; Anderson JR; Grundy PE; Dome JS
J Clin Oncol; 2018 Jan; 36(3):254-261. PubMed ID: 29211618
[TBL] [Abstract][Full Text] [Related]
4. Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study.
Chagtai T; Zill C; Dainese L; Wegert J; Savola S; Popov S; Mifsud W; Vujanić G; Sebire N; Le Bouc Y; Ambros PF; Kager L; O'Sullivan MJ; Blaise A; Bergeron C; Mengelbier LH; Gisselsson D; Kool M; Tytgat GA; van den Heuvel-Eibrink MM; Graf N; van Tinteren H; Coulomb A; Gessler M; Williams RD; Pritchard-Jones K
J Clin Oncol; 2016 Sep; 34(26):3195-203. PubMed ID: 27432915
[TBL] [Abstract][Full Text] [Related]
5. Cytogenetic abnormalities and clinical outcome in Wilms tumor: a study by the U.K. cancer cytogenetics group and the U.K. Children's Cancer Study Group.
Bown N; Cotterill SJ; Roberts P; Griffiths M; Larkins S; Hibbert S; Middleton H; Kelsey A; Tritton D; Mitchell C
Med Pediatr Oncol; 2002 Jan; 38(1):11-21. PubMed ID: 11835232
[TBL] [Abstract][Full Text] [Related]
6. Loss of Heterozygosity at Chromosome 16q Is a Negative Prognostic Factor in Korean Pediatric Patients with Favorable Histology Wilms Tumor: A Report of the Korean Pediatric Hematology Oncology Group (K-PHOG).
Park JE; Noh OK; Lee Y; Choi HS; Han JW; Hahn SM; Lyu CJ; Lee JW; Yoo KH; Koo HH; Jeong SY; Sung KW
Cancer Res Treat; 2020 Apr; 52(2):438-445. PubMed ID: 31505910
[TBL] [Abstract][Full Text] [Related]
7. Gain of 1q is a marker of poor prognosis in Wilms' tumors.
Segers H; van den Heuvel-Eibrink MM; Williams RD; van Tinteren H; Vujanic G; Pieters R; Pritchard-Jones K; Bown N;
Genes Chromosomes Cancer; 2013 Nov; 52(11):1065-74. PubMed ID: 24038759
[TBL] [Abstract][Full Text] [Related]
8. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group.
Grundy PE; Breslow NE; Li S; Perlman E; Beckwith JB; Ritchey ML; Shamberger RC; Haase GM; D'Angio GJ; Donaldson M; Coppes MJ; Malogolowkin M; Shearer P; Thomas PR; Macklis R; Tomlinson G; Huff V; Green DM;
J Clin Oncol; 2005 Oct; 23(29):7312-21. PubMed ID: 16129848
[TBL] [Abstract][Full Text] [Related]
9. Clinical Outcome and Biological Predictors of Relapse After Nephrectomy Only for Very Low-risk Wilms Tumor: A Report From Children's Oncology Group AREN0532.
Fernandez CV; Perlman EJ; Mullen EA; Chi YY; Hamilton TE; Gow KW; Ferrer FA; Barnhart DC; Ehrlich PF; Khanna G; Kalapurakal JA; Bocking T; Huff V; Tian J; Geller JI; Grundy PE; Anderson JR; Dome JS; Shamberger RC
Ann Surg; 2017 Apr; 265(4):835-840. PubMed ID: 27811504
[TBL] [Abstract][Full Text] [Related]
10. [Correlation of 1p/16q loss of heterozygosity and 1p gain with clinicopathological characteristics and prognosis in Wilms tumor].
Jia C; Yao XF; Zhang M; Guan XX; Wang JW; Song HC; He LJ
Zhonghua Bing Li Xue Za Zhi; 2024 Mar; 53(3):257-263. PubMed ID: 38433053
[No Abstract] [Full Text] [Related]
11. Profiling Loss of Heterozygosity Patterns in a Cohort of Favorable Histology Nephroblastoma Egyptian Patients: What is Consistent With the Rest of the World.
Fawzy M; Bahanassy A; Samir A; Hafez H
Pediatr Hematol Oncol; 2015; 32(8):548-56. PubMed ID: 26390800
[TBL] [Abstract][Full Text] [Related]
12. Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Children's Oncology Group AREN0532 and AREN0533 Study Report.
Dix DB; Fernandez CV; Chi YY; Mullen EA; Geller JI; Gratias EJ; Khanna G; Kalapurakal JA; Perlman EJ; Seibel NL; Ehrlich PF; Malogolowkin M; Anderson J; Gastier-Foster J; Shamberger RC; Kim Y; Grundy PE; Dome JS;
J Clin Oncol; 2019 Oct; 37(30):2769-2777. PubMed ID: 31449468
[TBL] [Abstract][Full Text] [Related]
13. 1q gain is a frequent finding in preoperatively treated Wilms tumors, but of limited prognostic value for risk stratification in the SIOP2001/GPOH trial.
Vokuhl C; Vogelgesang W; Leuschner I; Furtwängler R; Graf N; Gessler M; Dörner E; Pietsch T
Genes Chromosomes Cancer; 2014 Nov; 53(11):960-2. PubMed ID: 25044466
[No Abstract] [Full Text] [Related]
14. Prognostic impact of lymph node involvement and loss of heterozygosity of 1p or 16q in stage III favorable histology Wilms tumor: A report from Children's Oncology Group Studies AREN03B2 and AREN0532.
Evageliou N; Renfro LA; Geller J; Perlman E; Kalapurakal J; Paulino A; Dix D; Eklund MJ; Murphy AJ; Romao RLP; Ehrlich PF; Varela CR; Vallance K; Fernandez CV; Dome JS; Mullen EA
Cancer; 2024 Mar; 130(5):792-802. PubMed ID: 37902955
[TBL] [Abstract][Full Text] [Related]
15. Patterns of lymph node sampling and the impact of lymph node density in favorable histology Wilms tumor: An analysis of the national cancer database.
Saltzman AF; Carrasco A; Amini A; Aldrink JH; Dasgupta R; Gow KW; Glick RD; Ehrlich PF; Cost NG
J Pediatr Urol; 2018 Apr; 14(2):161.e1-161.e8. PubMed ID: 29133167
[TBL] [Abstract][Full Text] [Related]
16. Astrocyte elevated gene-1 overexpression in histologically favorable Wilms tumor is related to poor prognosis.
Guo F; Zhang LJ; Liu W; Wang G; Liu HY; Wang YL; Ma R; Wu RD
J Pediatr Urol; 2014 Apr; 10(2):317-23. PubMed ID: 24119914
[TBL] [Abstract][Full Text] [Related]
17. Response to the letter to the editor: 1q gain is a frequent finding in preoperatively treated Wilms tumors, but of limited prognostic value for risk satisfaction in the SIOP2009/Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH) trial.
Pritchard-Jones K; Williams R; Segers H; van den Heuvel-Eibrink M; Pieters R; van Tinteren H; Vujanic G; Bown N
Genes Chromosomes Cancer; 2015 Jun; 54(6):397-9. PubMed ID: 25820248
[No Abstract] [Full Text] [Related]
18. Risk stratification for wilms tumor: current approach and future directions.
Dome JS; Perlman EJ; Graf N
Am Soc Clin Oncol Educ Book; 2014; ():215-23. PubMed ID: 24857079
[TBL] [Abstract][Full Text] [Related]
19. Nomogram for personalized prognostic assessment of children with favorable histology Wilms tumor: A retrospective analysis.
Wang Z; Li J; Liu P; Xie X; Song H; Zhang W
Urol Oncol; 2024 Jun; 42(6):178.e1-178.e10. PubMed ID: 38522976
[TBL] [Abstract][Full Text] [Related]
20. Amplification and overexpression of CACNA1E correlates with relapse in favorable histology Wilms' tumors.
Natrajan R; Little SE; Reis-Filho JS; Hing L; Messahel B; Grundy PE; Dome JS; Schneider T; Vujanic GM; Pritchard-Jones K; Jones C
Clin Cancer Res; 2006 Dec; 12(24):7284-93. PubMed ID: 17189400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]